Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases

-15% su kodu: ENG15
431,95 
Įprasta kaina: 508,18 
-15% su kodu: ENG15
Kupono kodas: ENG15
Akcija baigiasi: 2025-03-03
-15% su kodu: ENG15
431,95 
Įprasta kaina: 508,18 
-15% su kodu: ENG15
Kupono kodas: ENG15
Akcija baigiasi: 2025-03-03
-15% su kodu: ENG15
2025-02-28 508.1800 InStock
Nemokamas pristatymas į paštomatus per 11-15 darbo dienų užsakymams nuo 10,00 

Knygos aprašymas

This book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases. Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected to significantly increase as the world population continues to grow older. An improved understanding of the etiological underpinnings of ocular degenerative diseases over the past decade has significantly bolstered ophthalmic drug discovery. In this volume, contributions from leading experts explore the unique challenges faced for ocular drug discovery and delivery providing the reader with detailed information on ocular pharmacokinetics, in vitro, ex vivo and in vivo models for retinal disease pathology and emerginggene therapy treatments. The book is intended for all researchers and clinicians who wish to increase their knowledge on the latest findings in ocular drug therapy.

Informacija

Serija: Topics in Medicinal Chemistry
Leidėjas: Springer Nature Switzerland
Išleidimo metai: 2021
Knygos puslapių skaičius: 284
ISBN-10: 3030566218
ISBN-13: 9783030566210
Formatas: 235 x 155 x 16 mm. Knyga minkštu viršeliu
Kalba: Anglų

Pirkėjų atsiliepimai

Parašykite atsiliepimą apie „Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases“

Būtina įvertinti prekę

Goodreads reviews for „Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases“